 Elizabeth Kessler
Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 8 | 2026 | 260 | 2.900 |
Why?
| | Prostatic Neoplasms | 14 | 2025 | 978 | 2.850 |
Why?
| | Carcinoma, Renal Cell | 8 | 2023 | 234 | 1.870 |
Why?
| | Kidney Neoplasms | 10 | 2023 | 412 | 1.860 |
Why?
| | Suicide, Assisted | 6 | 2024 | 31 | 1.680 |
Why?
| | Antineoplastic Agents | 11 | 2026 | 2201 | 1.600 |
Why?
| | Prostate-Specific Antigen | 3 | 2021 | 162 | 1.250 |
Why?
| | Physicians | 6 | 2024 | 949 | 0.930 |
Why?
| | Oncologists | 2 | 2024 | 46 | 0.870 |
Why?
| | Patient Care Planning | 1 | 2026 | 170 | 0.850 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 1961 | 0.760 |
Why?
| | Patient Preference | 1 | 2025 | 226 | 0.740 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1145 | 0.610 |
Why?
| | Orchiectomy | 3 | 2016 | 73 | 0.610 |
Why?
| | Anilides | 5 | 2023 | 84 | 0.600 |
Why?
| | Aged | 27 | 2026 | 25955 | 0.580 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.570 |
Why?
| | Abiraterone Acetate | 1 | 2017 | 15 | 0.510 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 2 | 2017 | 53 | 0.500 |
Why?
| | Plant Extracts | 1 | 2018 | 188 | 0.490 |
Why?
| | Prednisone | 1 | 2017 | 221 | 0.470 |
Why?
| | Capecitabine | 1 | 2015 | 57 | 0.470 |
Why?
| | Indazoles | 2 | 2014 | 82 | 0.460 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 31 | 0.460 |
Why?
| | Pyridines | 5 | 2023 | 603 | 0.450 |
Why?
| | Frailty | 1 | 2018 | 200 | 0.450 |
Why?
| | Imidazoles | 2 | 2014 | 246 | 0.430 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2015 | 58 | 0.430 |
Why?
| | Carcinoma, Papillary | 1 | 2015 | 77 | 0.430 |
Why?
| | Humans | 56 | 2026 | 144667 | 0.420 |
Why?
| | Deoxycytidine | 1 | 2015 | 222 | 0.420 |
Why?
| | Spinal Neoplasms | 1 | 2014 | 37 | 0.420 |
Why?
| | Neoplasms | 6 | 2023 | 2873 | 0.410 |
Why?
| | Quinazolines | 1 | 2015 | 266 | 0.410 |
Why?
| | Piperidines | 1 | 2015 | 219 | 0.410 |
Why?
| | Testicular Neoplasms | 3 | 2023 | 111 | 0.410 |
Why?
| | Neoplasm Metastasis | 5 | 2020 | 691 | 0.390 |
Why?
| | Immunotherapy | 1 | 2018 | 662 | 0.380 |
Why?
| | Canada | 5 | 2023 | 432 | 0.340 |
Why?
| | Male | 30 | 2025 | 72431 | 0.330 |
Why?
| | Geriatric Assessment | 4 | 2021 | 233 | 0.330 |
Why?
| | Protein Kinase Inhibitors | 2 | 2017 | 971 | 0.320 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2015 | 643 | 0.310 |
Why?
| | Aged, 80 and over | 7 | 2021 | 8284 | 0.300 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 76 | 0.300 |
Why?
| | Surveys and Questionnaires | 9 | 2025 | 6041 | 0.300 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 718 | 0.290 |
Why?
| | Aging | 2 | 2018 | 1938 | 0.280 |
Why?
| | Androgen Antagonists | 3 | 2020 | 92 | 0.270 |
Why?
| | Palliative Care | 4 | 2026 | 1011 | 0.260 |
Why?
| | Age Factors | 4 | 2026 | 3329 | 0.260 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 926 | 0.260 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1465 | 0.260 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 464 | 0.250 |
Why?
| | Caregivers | 2 | 2023 | 1062 | 0.250 |
Why?
| | Urothelium | 3 | 2019 | 33 | 0.250 |
Why?
| | Middle Aged | 16 | 2025 | 35971 | 0.240 |
Why?
| | Communication | 2 | 2024 | 972 | 0.240 |
Why?
| | Delphi Technique | 2 | 2026 | 330 | 0.240 |
Why?
| | Carcinoma, Transitional Cell | 2 | 2019 | 69 | 0.240 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 503 | 0.240 |
Why?
| | Treatment Outcome | 8 | 2025 | 11735 | 0.240 |
Why?
| | Malignant Atrophic Papulosis | 1 | 2025 | 1 | 0.240 |
Why?
| | Stress, Psychological | 1 | 2014 | 1148 | 0.230 |
Why?
| | Biopsy | 3 | 2025 | 1079 | 0.200 |
Why?
| | Penile Neoplasms | 1 | 2023 | 6 | 0.200 |
Why?
| | Subacute Care | 1 | 2024 | 82 | 0.200 |
Why?
| | Terminally Ill | 1 | 2023 | 40 | 0.190 |
Why?
| | Pilot Projects | 5 | 2023 | 1886 | 0.190 |
Why?
| | Bone Neoplasms | 2 | 2015 | 255 | 0.190 |
Why?
| | Molecular Targeted Therapy | 2 | 2018 | 437 | 0.190 |
Why?
| | Administration, Oral | 1 | 2025 | 851 | 0.180 |
Why?
| | Skilled Nursing Facilities | 1 | 2024 | 151 | 0.180 |
Why?
| | Quality of Life | 4 | 2022 | 3183 | 0.180 |
Why?
| | Female | 18 | 2025 | 78304 | 0.170 |
Why?
| | Medical Oncology | 2 | 2021 | 331 | 0.170 |
Why?
| | Adenosine Deaminase | 1 | 2021 | 43 | 0.170 |
Why?
| | Vasculitis | 1 | 2021 | 69 | 0.170 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5870 | 0.170 |
Why?
| | Lung Neoplasms | 1 | 2014 | 2660 | 0.160 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 238 | 0.160 |
Why?
| | Skin | 1 | 2025 | 762 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2023 | 201 | 0.160 |
Why?
| | Videoconferencing | 1 | 2020 | 65 | 0.160 |
Why?
| | Ureteral Neoplasms | 1 | 2019 | 1 | 0.150 |
Why?
| | Nephroureterectomy | 1 | 2019 | 2 | 0.150 |
Why?
| | Adult | 11 | 2025 | 40489 | 0.150 |
Why?
| | Hospice Care | 1 | 2022 | 226 | 0.150 |
Why?
| | Physical Examination | 1 | 2020 | 240 | 0.150 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 589 | 0.150 |
Why?
| | Rheumatology | 1 | 2020 | 133 | 0.140 |
Why?
| | Colorado | 3 | 2024 | 4558 | 0.140 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 21 | 0.140 |
Why?
| | United States | 6 | 2025 | 16018 | 0.140 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 63 | 0.140 |
Why?
| | Patient Selection | 2 | 2020 | 727 | 0.140 |
Why?
| | Frail Elderly | 1 | 2018 | 135 | 0.130 |
Why?
| | Wilms Tumor | 1 | 2018 | 86 | 0.130 |
Why?
| | Attitude of Health Personnel | 3 | 2024 | 1180 | 0.130 |
Why?
| | Patient Discharge | 1 | 2024 | 985 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 15 | 0.130 |
Why?
| | Checklist | 1 | 2018 | 111 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 990 | 0.130 |
Why?
| | Prognosis | 4 | 2023 | 4312 | 0.120 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.120 |
Why?
| | Taxoids | 1 | 2017 | 116 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2022 | 330 | 0.120 |
Why?
| | Cisplatin | 1 | 2018 | 339 | 0.120 |
Why?
| | Documentation | 1 | 2018 | 198 | 0.120 |
Why?
| | Nutritional Status | 1 | 2018 | 351 | 0.120 |
Why?
| | Mass Screening | 2 | 2021 | 1348 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 381 | 0.110 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2021 | 230 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 360 | 0.110 |
Why?
| | Radiation Tolerance | 1 | 2015 | 103 | 0.110 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 50 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 153 | 0.100 |
Why?
| | Decision Making | 1 | 2022 | 973 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 881 | 0.100 |
Why?
| | Neoplasms, Complex and Mixed | 1 | 2013 | 7 | 0.100 |
Why?
| | Demography | 1 | 2014 | 287 | 0.100 |
Why?
| | Carcinoma, Medullary | 1 | 2013 | 16 | 0.100 |
Why?
| | Lymphatic Metastasis | 1 | 2014 | 334 | 0.100 |
Why?
| | Risk Assessment | 2 | 2023 | 3729 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 238 | 0.090 |
Why?
| | Energy Metabolism | 1 | 2018 | 927 | 0.090 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 254 | 0.090 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2014 | 539 | 0.090 |
Why?
| | Feasibility Studies | 3 | 2023 | 1103 | 0.090 |
Why?
| | Pediatrics | 1 | 2020 | 1121 | 0.090 |
Why?
| | Bone Diseases | 1 | 2012 | 61 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 848 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.090 |
Why?
| | Clinical Competence | 1 | 2020 | 1237 | 0.090 |
Why?
| | Drugs, Investigational | 1 | 2011 | 31 | 0.090 |
Why?
| | Needs Assessment | 1 | 2014 | 401 | 0.090 |
Why?
| | Health Personnel | 1 | 2018 | 746 | 0.090 |
Why?
| | Radiosurgery | 1 | 2015 | 398 | 0.080 |
Why?
| | Urinary Bladder | 1 | 2013 | 192 | 0.080 |
Why?
| | Telemedicine | 1 | 2020 | 957 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2012 | 212 | 0.080 |
Why?
| | Sarcoma | 1 | 2013 | 203 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 1505 | 0.080 |
Why?
| | Disease Progression | 1 | 2018 | 2847 | 0.080 |
Why?
| | Pyrimidines | 1 | 2014 | 519 | 0.080 |
Why?
| | Sulfonamides | 1 | 2014 | 579 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1569 | 0.080 |
Why?
| | Recombinant Fusion Proteins | 1 | 2012 | 667 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 441 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 532 | 0.070 |
Why?
| | B7-H1 Antigen | 2 | 2022 | 242 | 0.070 |
Why?
| | Quality Improvement | 1 | 2018 | 1287 | 0.070 |
Why?
| | Survival Rate | 3 | 2019 | 2089 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 1370 | 0.060 |
Why?
| | Nephrectomy | 2 | 2018 | 158 | 0.060 |
Why?
| | Cohort Studies | 1 | 2015 | 5957 | 0.050 |
Why?
| | Conscience | 1 | 2024 | 9 | 0.050 |
Why?
| | Risk Factors | 1 | 2018 | 10796 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 84 | 0.050 |
Why?
| | Drug Interactions | 2 | 2017 | 401 | 0.050 |
Why?
| | Retrospective Studies | 4 | 2023 | 17149 | 0.050 |
Why?
| | Morals | 1 | 2023 | 78 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2025 | 1268 | 0.050 |
Why?
| | Telephone | 1 | 2023 | 176 | 0.050 |
Why?
| | SEER Program | 1 | 2023 | 226 | 0.050 |
Why?
| | Young Adult | 4 | 2023 | 14122 | 0.040 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2021 | 22 | 0.040 |
Why?
| | Agammaglobulinemia | 1 | 2021 | 36 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 408 | 0.040 |
Why?
| | Adolescent | 4 | 2025 | 22409 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 79 | 0.040 |
Why?
| | Fatigue | 1 | 2023 | 363 | 0.040 |
Why?
| | Prostate | 1 | 2022 | 158 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2021 | 376 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5414 | 0.040 |
Why?
| | Europe | 1 | 2020 | 419 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 1056 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 729 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 310 | 0.040 |
Why?
| | Central Nervous System | 1 | 2020 | 279 | 0.030 |
Why?
| | Survivors | 1 | 2022 | 519 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 768 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 779 | 0.030 |
Why?
| | Pain | 1 | 2023 | 785 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1322 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 52 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2023 | 1742 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 479 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 864 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1263 | 0.030 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 149 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 142 | 0.030 |
Why?
| | Cytokines | 1 | 2021 | 2045 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3888 | 0.020 |
Why?
| | beta-Galactosidase | 1 | 2013 | 76 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2020 | 944 | 0.020 |
Why?
| | Breeding | 1 | 2013 | 63 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 153 | 0.020 |
Why?
| | Hyperplasia | 1 | 2013 | 177 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.020 |
Why?
| | Keratins | 1 | 2013 | 171 | 0.020 |
Why?
| | Organ Specificity | 1 | 2013 | 311 | 0.020 |
Why?
| | Integrases | 1 | 2013 | 122 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 364 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 199 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2013 | 124 | 0.020 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2013 | 427 | 0.020 |
Why?
| | Animals | 4 | 2017 | 37948 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1494 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 4081 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 925 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1705 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2012 | 632 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1847 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2019 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2754 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2184 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 7140 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1360 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7994 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2018 | 6399 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1319 | 0.010 |
Why?
| | Pregnancy | 1 | 2018 | 7122 | 0.010 |
Why?
| | Mice | 2 | 2013 | 18261 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3414 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2489 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3523 | 0.010 |
Why?
| | Child | 1 | 2023 | 22600 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4539 | 0.010 |
Why?
|
|
Kessler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|